Zotepine for schizophrenia (Q24244343)

https://api.crossref.org/works/10.1002%2F14651858.CD001948.PUB2

Improvement of cognitive function in schizophrenic patients receiving clozapine or zotepine: results from a double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001948.PUB2

Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001948.PUB2

[Effectiveness of zotepine in therapy-refractory psychoses. An open, multicenter study in eight psychiatric clinics]

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001948.PUB2

Effect of zotepine, olanzapine and risperidone on hostility in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001948.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001948.PUB2

Comparative placebo-controlled pharmacodynamic studies with zotepine and clozapine utilizing pharmaco-EEG and psychometry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001948.PUB2

Improving the quality of reporting of randomized controlled trials. The CONSORT statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001948.PUB2

Statistics notes. Trials randomised in clusters

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001948.PUB2

New dimensions in the pharmacologic treatment of schizophrenia and related psychoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001948.PUB2

Bias in treatment assignment in controlled clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001948.PUB2

The unit of analysis error in studies about physicians' patient care behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001948.PUB2

Issues in the meta-analysis of cluster randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001948.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001948.PUB2

Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001948.PUB2

Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001948.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001948.PUB2

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001948.PUB2

The new atypical antipsychotics. A lack of extrapyramidal side-effects and new routes in schizophrenia research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001948.PUB2

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001948.PUB2

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001948.PUB2

A New Depression Scale Designed to be Sensitive to Change

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001948.PUB2

An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001948.PUB2

Frontal-striatal cognitive deficits in patients with chronic schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001948.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001948.PUB2

A rating scale for tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001948.PUB2

Clinical effectiveness of zotepine in treatment of negative schizophrenic symptoms. Results of an open and a double-blind controlled trial

21 January 2018

1 reference

12 December 2020

Zotepine vs. haloperidol in paranoid schizophrenia: a double-blind trial

1 reference

12 December 2020

Zotepine versus perazine in patients with paranoid schizophrenia: a double-blind controlled trial of its effectiveness

1 reference

12 December 2020

Detecting skewness from summary information

1 reference

12 December 2020

Effectiveness and tolerance of zotepine in a double-blind comparison with perazine in schizophrenic patients

1 reference

12 December 2020

Comparison of efficacy of zotepine and thiothixene in schizophrenia in a double-blind study

1 reference

12 December 2020

Factors which can make patients difficult to treat.

1 reference

12 December 2020

Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia

1 reference

12 December 2020

A comparison of an atypical and typical antipsychotic, zotepine versus haloperidol in patients with acute exacerbation of schizophrenia: a parallel-group double-blind trial

1 reference

12 December 2020

Double-blind comparison of 3 x 75 mg zotepine und 3 x 4 mg haloperidol in acute schizophrenic patients

1 reference

12 December 2020

Zotepine in the prevention of recurrence: a randomised, double-blind, placebo-controlled study for chronic schizophrenia.

1 reference

12 December 2020

Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review

1 reference

12 December 2020

Zotepine for schizophrenia.

1 reference

12 December 2020

1 reference

12 December 2020

A rating scale for extrapyramidal side effects

1 reference

12 December 2020

[Zotepine vs. haloperidol in paranoid schizophrenia: a double-blind study]

1 reference

12 December 2020

Practice guideline for the treatment of patients with schizophrenia. American Psychiatric Association

1 reference

12 December 2020

Development and testing of the Medical Outcomes Study 36-Item Short Form Health Survey summary scale scores in the United Kingdom. Results from a large-scale survey and a clinical trial

1 reference

12 December 2020

Zotepine in the treatment of schizophrenic patients with prevailingly negative symptoms. A double-blind trial vs. haloperidol

1 reference

12 December 2020

Zotepine: preclinical tests predict antipsychotic efficacy and an atypical profile

1 reference

12 December 2020

A placebo-controlled comparison of zotepine versus chlorpromazine in patients with acute exacerbation of schizophrenia

1 reference

12 December 2020

[Problems in evaluating new antipsychotic drugs]

1 reference

12 December 2020

Adverse effects of the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations

1 reference

12 December 2020

The relationship of pharmacology to side effects

1 reference

12 December 2020